The Life Sciences Sector Group is a global team of professionals whose focus is advising clients in the life sciences industries which includes the fields of biotechnology, pharmaceuticals, biomedical technologies, life systems technologies, nutraceuticals, environmental and biomedical devices.
Making the correct real estate decisions means being in the right location, at the right cost and at the right time for your staff, your clients and your business. Our Life Sciences Sector Group shares best practice, research and knowledge from the real estate industry to assist in all aspects of a life science company’s real estate needs.
The sector has witnessed a downturn in recent years. Fewer start ups, patent expirations of well-known drugs, the global economic and market shifts, technology changes, increasing pressure from investors for return on equity, a decline in public funding and outsourcing of former core business functions all impacted the industry. Further challenges include:
- Expanding and scaling-up commercial operations
- Attracting top scientific talent
- Adapting real estate needs to meet emerging therapeutic fields
- Migrating to lower cost environments
- Shedding unneeded obligations
- Monetizing underutilised assets
How Can We Add Value?
The fundamental real estate challenge for the life sciences company is to ensure the greatest measure of flexibility for its expensive, highly-specialised, long-term fixed assets.
The Life Sciences Sector Group offers industry leaders a partner in meeting these challenges. Our professionals have decades of experience covering all sectors - pharmaceutical, biopharmaceutical, biotechnology, and medical devices - and all asset classes - R&D, manufacturing, distribution, and office. With clients spanning four continents, we help to leverage the global market and effectively manoeuvre through a dynamic landscape in order to improve margins, maximize productivity and remain competitive in every sector.
Drawing from this broad experience, our team of consultants and transaction specialists add a unique value by helping align real estate portfolios with company business goals. Some of the services we provide are:
From real estate due diligence for merger and acquisition activity, to location analysis and portfolio optimisation programmes, we help you deliver against your business objectives while reducing risk.
We help you optimise the value of your property while considering the impact on your firm’s balance sheet; implementing everything from global lease administration, lease abstraction and database management to strategic analysis and decision-making support.
Our transaction specialists can advise and facilitate smoother transactions, whether it’s a full property search and relocation or simply a lease renewal.
Project and change management
We help you deliver real estate projects on time, within budget, to specification and in keeping with organizational and people objectives. Our team can help you manage the implementation of projects – from fit-outs to new builds – as well as the impact on your operations and people, through extensive move management and change management services. Other services include design, project monitoring and consulting.
We use best-in-class processes, procedures, and technology to ensure your work environments are safe and highly-productive. Our teams help you balance costs, manage and mitigate operational risk, and achieve client Corporate Social Responsibility goals through progressive sustainability and energy management programs.
We help to reduce the environmental impact of your property to comply with legislation and to save costs.
Experience and Resources
Our life sciences clients benefit from an experienced team, including sector specialists in markets across Asia, the Americas, Europe and the Middle East; all backed by our global network of 15,000 employees worldwide and our industry-leading technology and collaboration platforms.
We work with a broad range of clients within the life sciences sector, including Abbott, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Quintiles, Novartis and Zimmer.